Percutaneous liver biopsy and revised coagulation guidelines: a 9-year experience

Area of Science:

• Hepatology
• Interventional Radiology
• Coagulation Medicine

Background:

• Percutaneous liver biopsy requires careful coagulation assessment to minimize bleeding.
• Previous guidelines (SIR) mandated stricter parameters (INR ≤ 1.5, platelets ≥ 50,000).
• The impact of revised, less stringent guidelines on complication rates and resource utilization was unclear.

Purpose of the Study:

• To evaluate if revised, less stringent pre-procedural coagulation guidelines for percutaneous liver biopsy increase hemorrhagic complications.
• To assess the effect of guideline changes on fresh frozen plasma (FFP) and platelet utilization.
• To determine the relationship between INR, platelet levels, blood product administration, and bleeding complications.

Main Methods:

• Retrospective review of 1846 percutaneous liver biopsies in 1740 patients.
• Comparison of outcomes under strict SIR guidelines versus revised departmental guidelines (INR ≤ 2.0, platelets ≥ 25,000).
• Analysis of departmental complication rates, blood product usage, and individual patient risk factors (INR, platelets).

Main Results:

• Fewer hemorrhagic complications occurred department-wide after adopting less stringent guidelines (1.6% vs. 3.4%, p=0.0192).
• Significant decreases in pre-procedural FFP (0.8% vs. 3.9%) and platelet transfusions (0.3% vs. 1.2%) were observed.
• Increased INR and decreased platelet counts correlated with higher individual bleeding risk, but transfusions did not mitigate this risk.

Conclusions:

• Less stringent coagulation guidelines (INR ≤ 2.0, platelets ≥ 25,000) for liver biopsy are safe and do not increase departmental hemorrhagic complications.
• These revised guidelines significantly reduce the need for pre-procedural blood product administration.
• While individual bleeding risk is linked to INR and platelet levels, prophylactic transfusions did not prove effective in preventing complications.